ebomi
Colour theme
Sign in
Insider · CIK 0001694560

New Enterprise Associates 16, L.P.

CIK 0001694560 Name as filed on the most recent filing

Filed as New Enterprise Associates 16, L.P. (17)

21 transaction lines · from 17 filings · filed 2019-02-19 to 2025-10-06 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-10-02 S, Open-market sale NeueHealth, Inc.NEUE 1,890, disposed Open Form 4 filing 0001193125-25-232130
2024-12-23 P, Open-market purchase Marker Therapeutics, Inc.MRKR 1,773,600, acquired Open Form 4 filing 0000950170-24-139630
2022-05-25 S, Open-market sale Genocea Biosciences, Inc.GNCA 362,720, disposed Open Form 4 filing 0001209191-22-032327
2022-05-24 S, Open-market sale Genocea Biosciences, Inc.GNCA 387,943, disposed Open Form 4 filing 0001209191-22-032327
2022-04-11 P, Open-market purchase Trevi Therapeutics, Inc.TRVI 4,999,998, acquired Open Form 4 filing 0001209191-22-024301
2021-12-22 S, Open-market sale Metacrine, Inc.MTCR 2 lines 444,853, disposed Open Form 4 filing 0001209191-21-071265
2021-12-10 S, Open-market sale Metacrine, Inc.MTCR 49,630, disposed Open Form 4 filing 0001209191-21-071265
2021-10-18 P, Open-market purchase Trevi Therapeutics, Inc.TRVI Not reported Open Form 4 filing 0001209191-21-061090
2021-03-16 P, Open-market purchase Marker Therapeutics, Inc.MRKR 9,999,999, acquired Open Form 4 filing 0001209191-21-021809
2020-12-04 P, Open-market purchase Regulus Therapeutics Inc.RGLS 2,735,930, acquired Open Form 4 filing 0001209191-20-061962
2020-09-18 P, Open-market purchase Metacrine, Inc.MTCR 9,999,990, acquired Open Form 4 filing 0001209191-20-051525
2020-07-24 P, Open-market purchase Genocea Biosciences, Inc.GNCA 7,090,335, acquired Open Form 4 filing 0001209191-20-043862
2020-06-30 P, Open-market purchase Akouos, Inc.AKUS 9,999,995, acquired Open Form 4 filing 0001209191-20-039849
2020-04-03 S, Open-market sale Trevi Therapeutics, Inc.TRVI 1,500, disposed Open Form 4 filing 0001209191-20-024314
2019-07-22 P, Open-market purchase Mirum Pharmaceuticals, Inc.MIRM 6,750,000, acquired Open Form 4 filing 0001209191-19-043052
2019-06-24 P, Open-market purchase Genocea Biosciences, Inc.GNCA 9,999,997, acquired Open Form 4 filing 0001209191-19-038946
2019-05-09 P, Open-market purchase Trevi Therapeutics, Inc.TRVI 2 lines 25,000,000, acquired Open Form 4 filing 0001209191-19-029388
2019-05-07 P, Open-market purchase Regulus Therapeutics Inc.RGLS 1,227,640, acquired Open Form 4 filing 0001209191-19-028589
2019-02-14 P, Open-market purchase Genocea Biosciences, Inc.GNCA 4,688,619, acquired Open Form 4 filing 0001209191-19-011145

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. New Enterprise Associates 16, L.P., insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001694560

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.